***N*-(3-Chlorophenyl)-3-(pyridin-3-yl)-[1,2,4]triazolo[4,3-a]pyrazine-5-carboxamide, OSM-S-263**

****

Representative Example: http://malaria.ourexperiment.org/uri/6d2

Prepared according to General Procedure **F** from: **OSM-S-XXX** (100 mg, 0.28 mmol) to give the title compound as a tan powder (50 mg, 50%); **m.p.** 196–197 ˚C; **IR** νmax (film) /cm-1 3058, 1681, 1594, 1542, 1480, 1425, 1313; **1H NMR** (400 MHz, DMSO-d*6*) δ: 11.07 (1H, s), 9.71 (1H, s), 8.79 (1H, dd, *J* 2.3, 1.1), 8.55 (1H, dd, *J* 4.9, 1.6), 8.38 (1H, s), 8.01 (1H, dt, *J* 7.9, 2.0), 7.42 (1H, dd, *J* 5.2, 1.0), 7.41 (1H, t, *J* 2.2), 7.40 (1H, dd, *J* 5.0, 1.1), 7.31 (1H, t, *J* 8.1), 7.21 (1H, ddd, *J* 8.2, 1.8, 1.0), 7.18 (1H, ddd, *J* 7.9, 2.0, 1.0); **13C NMR** (100 MHz, DMSO-d*6*) δ: 157.85, 151.10, 149.02, 146.81, 146.45, 145.75, 139.09, 136.30, 133.33, 131.08, 130.87, 124.94, 124.53, 124.45, 123.71, 119.85, 118.78; **m/z** (ESI+) 351 [M+H]+; **HRMS** (APCI+) found 351.07526 [M+H]+, C17H12ClN6O requires 351.0755.

*O=C(NC1=CC=CC(Cl)=C1)C2=CN=CC3=NN=C(C4=CN=CC=C4)N32*

*InChI=1S/C17H11ClN6O/c18-12-4-1-5-13(7-12)21-17(25)14-9-20-10-15-22-23-16(24(14)15)11-3-2-6-19-8-11/h1-10H,(H,21,25)*